REGiM - A randomised controlled trial of prolonged treatment with darbepoetin alpha (EPO), with or without recombinant human granulocyte colony stimulating factor (G-CSF), versus best supportive care in patients with low-risk myelodysplastic syndromes (MDS).
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2016
At a glance
- Drugs Darbepoetin alfa (Primary) ; Filgrastim (Primary)
- Indications Aplastic anaemia; Neutropenia; Refractory anaemia; Sideroblastic anaemia
- Focus Therapeutic Use
- Acronyms REGiM
- 27 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.
- 30 Jun 2010 New trial record